|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 108 USD | +1.69% |
|
+6.47% | +8.57% |
| Apr. 24 | Sector Update: Health Care Stocks Slipping Late Afternoon | MT |
| Apr. 24 | Moderna to Collaborate With OpenAI to Launch New Generation of Medicines | MT |
Jan 26 (Reuters) - Moderna Inc said on Wednesday it had dosed the first participant in a mid-stage study testing its Omicron-specific booster vaccine candidate.
The company also reported data showing that neutralizing antibodies against the Omicron COVID-19 variant declined 6.3-fold from peak levels six months after a third booster dose of its vaccine but remained detectable. (Reporting by Amruta Khandekar; Editing by Devika Syamnath)
| 1st Jan change | Capi. | |
|---|---|---|
| +8.57% | 40.65B | |
| +1.51% | 42.59B | |
| +49.22% | 40.57B | |
| -12.36% | 26.77B | |
| +8.92% | 24.81B | |
| -25.13% | 18.17B | |
| +29.17% | 12.05B | |
| -3.12% | 11.7B | |
| +6.35% | 11.1B | |
| -16.98% | 9.85B |
MODERNA, INC. 
